Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa prophylactic intranasal PrEP-001 challenge study in healthy adults exposed to HRV-16
2015-005492-25Phase 2Completed
- Sponsor
- PrEP Biopharm
- Start
- Jan 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of polyinosine-polycytidylic acid in rhinoviral infection and nasopharyngitis (3 arms), sponsored by PrEP Biopharm. Started Jan 2016; status: completed.
02
Drugs
polyinosine-polycytidylic acid
03
Conditions
rhinoviral infectionnasopharyngitis
Beyond the preview
Go deeper on 2015-005492-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005492-25.